Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 12 of 12 for “"CD22"”.
-
Generierung von chimären Mäusen mit Mutationen in der Signalleitungs-Domäne von CD22 und Untersuchungen zur Funktion von CD22 in Knockout-Mäusen
… die Untersuchung von Aspekten der Funktion von CD22, einem B-Zell spezifischen Transmembran-Rezeptor der Siglec-Familie (Sialinsäure-bindende Immunglobulin-ähnliche Lectine). Mit der äußersten der 7 extrazellulären Ig-ähnlichen Domänen kann CD22 spezifisch mit a2,6-Sialinsäure interagieren. In …
-
Der inhibitorische Einfluss von CD22 auf das B-Zellrezeptorsignal nach Stimulation der B-Zelle
CD22 ist ein B-zellspezifisches Transmembranprotein der Immunglobulin (Ig)-Superfamilie. Es übernimmt zwei unterschiedliche Aufgaben. Zum einen hat CD22 eine inhibitorische Wirkung auf das BZR-Signal. Nach BZR-Ligation lagert sich die Tyrosin-Phosphatase SHP-1 an die cytoplasmatische Domäne von …
-
Design, Development, Characterization and Testing of CD22 Targeted Long Circulating Liposomal Drug Delivery Systems for B Cell Malignancies
… liposomal formulations for targeted delivery to CD22 overexpressing B cell cancers. Liposomes were prepared by the classical Bangham method followed by size reduction by extrusion. Anti-CD22 Fab’ were generated and conjugated to the long circulating AD 198 liposomes by thioether bonds. …
-
Verwendung von Gene-Targeting-Techniken zur Etablierung neuer Mauslinien mit Mutationen in B-Zell-Signalwegen
… mit dem B-Zell spezifischen Oberflächenprotein CD22, einem Mitglied der Siglec (Sialinsäure bindende Igähnliche Lektine) Proteinfamilie. Dieses Transmembranprotein besitzt sieben extrazelluläre Immunoglobulin-ähnliche Domänen und kann über die äußerste V-set Domäne seine Liganden: α2,6 …
-
Regulation of Protective B cell Anti-Tumor Responses
… TACAs is governed by the inhibitory molecule CD22, which is constitutively expressed by B cells. CD22, is a sialic acid-binding, Ig-like, lectin receptor (Siglec), and was found to significantly suppress antigen-specific antibody responses to mucins bearing sialylated TACAs. Inhibition of CD22 …
-
Inorganic nanoparticles for applications in biomedical sciences
… because of its complex molecular pathology. CD22 is an adhesion molecule that is shown to be broadly expressed on NSCLC cell lines. Hence, in this project, we developed CD22 targeted gold nanoparticles to deliver Pt(IV) complex for the treatment of NSCLC. Synthesis and characterization of …
-
Towards An Understanding Of The Etiology Of Abdominal Aortic Aneurysms: Identification Of Genes Implicated In Aaa Risk And Development
… genes, <em>CEBPG</em>, <em>PEPD</em> and <em>CD22</em>, that had both functions relevant to AAA and expression in AAA tissue exhibited nominal association and further studied by DNA sequencing of exons. Sequence variants were identified in <em>PEPD</em> and <em>CD22</em>, but not …
-
The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma
… directed to other<br/>surface molecules (CD32b, CD22, CD37) did not exhibit cooperative effect.<br/>Analysis of apoptotic pathways demonstrated that PARP cleavage and<br/>caspase processing is significantly higher in cells receiving both treatments.<br/>Co-treatment of Ramos cells with the pan …
-
Chimärer anti-Tumor/CD3 zeta-Kette–Rezeptor („T-Body“) für die Therapie von humanen B-Zell-Neoplasien
… ein „T-Body“ gegen den B-Zell-Lymphom-Marker CD22 generiert. Der „T-Body“ setzt sich aus drei Domänen zusammen: einer Signal-, Transmembran- und einer extrazellulären Domäne. Nach Transfektion exprimieren und präsentieren T-Zellen diesen „T-Body“ auf ihrer Oberfläche und werden damit in die …
-
Development of SNAP-tag-based fusion proteins targeting HIV-1 viral reservoirs
… for therapy of refractory leukaemia. The anti-CD22 recombinant IT Moxetumomab pasudotox based on Pseudomonas aeruginosa exotoxin A (ETA) has been FDA approved to treat hairy cell leukaemia. Moxetumomab pasudotox targets the antigen CD22 found on the surface of tumour cells. The HIV neutralizing …
-
Targeting the CD19/CD21 complex on B cells in the mixed lymphocyte reaction
… a resting state with the concourse of the anti-CD22 antibody epratuzumab, inducing reduction in surface CD19/CD21 complex, would mitigate their responsiveness to allopeptides and thus, prevent the acquisition of potent antigen presenting functions. Furthermore, the combination with C3d …
-
CD40 stimulation activates ‘post-activated’ B Cells which are hyporesponsive to B Cell receptor and toll-like receptor 9 stimulation in autoimmunity
… recruitment of SHP-1 to the negative co-receptor CD22 in SLE, RA and pSS peripheral CD19+ B cells were increased compared to HDs. Signaling abnormalities of SLE, RA and pSS B cells did not correlate to differences in tonic phosphorylation or baseline expression of signaling molecules (Syk, Btk, 1 …